Fundraising Fox

Apollo Health VenturesFull Portfolio

7 tracked investments · listed companies and verified rows first

Bionyrabionyra.cominJun 2026 · $165M✓ verified

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.

BiotechHealthtech

Frédéric Marrache(Co-founder & CEO)in

Co-investorsJeito CapitalSanofi VenturesSofinnova PartnersVIVES PartnersSixty Degree Capital

Boostertxboostertx.comin✓ verified

Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools.

BiotechDeep TechLongevity

Diogo R. Feleciano(Co-Founder & CSO)Darci J. Trader(Scientific Co-Founder / Advisor)João Ribas(Interim-CBO)

Co-investorsNovo HoldingsKorify Capital

Haya Therapeuticshayatx.comin𝕏✓ verified

HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.

AI & Machine LearningBiotechDeep TechHealthtech

Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)Daniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in

Co-investorsBroadview VenturesSofinnova Partners+ND Capital4see Ventures

Samsarasamsaratherapeutics.com✓ verified

Samsara Therapeutics develops small-molecule therapeutics that activate autophagy to slow the progression of age-related neurodegenerative diseases such as ALS, Parkinson's, and Charcot-Marie-Tooth disease.

BiotechDeep TechLongevityBoston, US

Co-investorsCoastCapKorify Capital

Nula Therapeuticsin

BiotechSt. Petersburg, US

Christopher Shepard(Executive Officer, Director)Jarod Rutledge(Director)

BoardNils Regge(Director)

Co-investorsKorify Capital

Refoxyrefoxy.comin

Refoxy is a science-driven company focused on drug discovery, medicinal chemistry, and bioinformatics.

BiotechDeep TechHealthtechLongevity

Victor Bustos(Co-Founder & CEO)inWolfgang Link(Scientific Co-founder & Advisor)inAndrew Pierce(Chief Science Officer)in

Co-investorsKorify CapitalBoehringer Ingelheim Venture FundHTGF

Therini Biotherinibio.cominMay 2025 · $39M

Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.

BiotechDigital HealthHealthtechMedical DevicesSacramento, US

Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in

BoardOlga Danilchanka(Director)Laia Crespo-Martin(Director)

Co-investorsMRL Ventures FundSanofi VenturesSV Health InvestorsAngelini VenturesMitsui Global InvestmentDementia Discovery Fund+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.